It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumor-derived exosomes (TEXs) contain enriched miRNAs, and exosomal miRNAs can affect tumor growth, including cell proliferation, metastasis, and drug resistance through cell-to-cell communication. We investigated the role of exosomal miR-1260b derived from non-small cell lung cancer (NSCLC) in tumor progression. Exosomal miR-1260b induced angiogenesis by targeting homeodomain-interacting protein kinase-2 (HIPK2) in human umbilical vein endothelial cells (HUVECs). Furthermore, exosomal miR-1260b or suppression of HIPK2 led to enhanced cellular mobility and cisplatin resistance in NSCLC cells. In patients with NSCLC, the level of HIPK2 was significantly lower in tumor tissues than in normal lung tissues, while that of miR-1260b was higher in tumor tissues. HIPK2 and miR-1260b expression showed an inverse correlation, and this correlation was strong in distant metastasis. Finally, the expression level of exosomal miR-1260b in plasma was higher in patients with NSCLC than in healthy individuals, and higher levels of exosomal miR-1260b were associated with high-grade disease, metastasis, and poor survival. In conclusion, exosomal miR-1260b can promote angiogenesis in HUVECs and metastasis of NSCLC by regulating HIPK2 and may serve as a prognostic marker for lung cancers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)
2 AMIST, University of Ulsan, College of Medicine, Department of Biomedical Sciences, Asan Medical Center, Seoul, South Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)
3 University of Ulsan, College of Medicine, Department of Convergence Medicine, Asan Medical Center, Seoul, South Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)
4 University of Ulsan, College of Medicine, Department of Pulmonology and Critical Care Medicine, Asan Medical Center, Seoul, South Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667); University of Ulsan, College of Medicine, Department of Oncology, Asan Medical Center, Seoul, South Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)
5 University of Ulsan, College of Medicine, Department of Oncology, Asan Medical Center, Seoul, South Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)